SCNLF (Scancell Holdings) Research & Development: $16.93 Mil (TTM As of Oct. 2025)


SCNLF Scancell Holdings PLC SCNLF
20 GF Score
Price $0.28
! 2 Warning Signs
View Full Analysis

What is Scancell Holdings Research & Development?

Scancell Holdings SCNLF 20 Research & Development is $16.93 Mil as of Oct. 2025. GuruFocus rates SCNLF with a GF Score™ of 20/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Scancell Holdings's Research & Development for the six months ended in Oct. 2025 was $8.20 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Oct. 2025 was $16.93 Mil.

Scancell Holdings  (OTCPK:SCNLF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Scancell Holdings Research & Development Related Terms

Scancell Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for Scancell Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scancell Holdings Research & Development Chart

Scancell Holdings Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.87 12.26 14.50 16.11 19.30

Scancell Holdings Semi-Annual Data
Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Apr20 Oct20 Apr21 Oct21 Apr22 Oct22 Apr23 Oct23 Apr24 Oct24 Apr25 Oct25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.93 8.98 10.49 8.73 8.20
SCNLF
20GF Score
Scancell Holdings PLC SCNLF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scancell Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Oct. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $16.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $16.93 Mil mean?
Scancell Holdings (SCNLF) has a Research & Development of $16.93 Mil as of Oct. 2025. Research and development expense is the total cost for research and development activities. View historical data on Scancell Holdings and its competitors.
Is Scancell Holdings' Research & Development too high?
Scancell Holdings' current Research & Development is $16.93 Mil. Overall, Scancell Holdings has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Scancell Holdings' Research & Development compare to VRTX and REGN?
Scancell Holdings' Research & Development of $16.93 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Scancell Holdings and its competitors. Scancell Holdings's current Research & Development is $16.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scancell Holdings stock overvalued right now?
Scancell Holdings (SCNLF) has a current Research & Development of $16.93 Mil. The current Research & Development is $16.93 Mil. Scancell Holdings' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Scancell Holdings (SCNLF), the current Research & Development is $16.93 Mil as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scancell Holdings Business Description

Other Exchanges SCLP:UKSCP:Germany
Address Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
20GF Score

Get the complete analysis for SCNLF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.28
Price